Do all patients with breast cancer benefit from neoadjuvant chemotherapy?

참고문헌 (11)

1. Wolmark N, "Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18", J Natl Cancer Inst Monogr, 30, pp.96~102 (2001)
2. Rastogi P, "Preoperative chemotherapy : updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27", J Clin Oncol, 26, pp.778~785 (2008)
3. Mauri D, "Neoadjuvant versus adjuvant systemic treatment in breast cancer : a meta-analysis", J Natl Cancer Inst, 97, pp.188~194 (2005)
4. Cortazar P, "Pathological complete response and long-term clinical benefit in breast cancer : the CTNeoBC pooled analysis", Lancet, 384, pp.164~172 (2014)
5. Mamounas EP, "Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer : results from NSABP B-28", J Clin Oncol, 23, pp.3686~3696 (2005)
6. Henderson IC, "Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer", J Clin Oncol, 21, pp.976~983 (2003)
7. "NCCN guidelines breast cancer" (2020)[URL]
8. Hye Sung Won, "Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer", The Korean Journal of Internal Medicine, 35(6), pp.1489~1496 (2020), 대한내과학회[DOI]
9. Papadimitriou K, "Neoadjuvant therapy for locally advanced breast cancer : focus on chemotherapy and biological targeted treatments’ armamentarium", J Thorac Dis, 2, pp.160~170 (2010)
10. Hirano A, "The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer", Anticancer Res, 26(1B), pp.581~584 (2006)
11. Khasraw M, "Epirubicin : is it like doxorubicin in breast cancer? A clinical review", Breast, 21, pp.142~149 (2012)

관련 논문AI추천